Summary of patients who received less than 4 cycles of treatment (all randomized patients)
| Patients, n (%) . | Guadecitabine (n = 408) . | TC (n = 407) . |
|---|---|---|
| <4 cycles | 173 (42) | 166 (41) |
| Primary reason for receiving <4 cycles | ||
| Randomized, but not treated | 7 (2) | 15 (4) |
| AE | 26 (6) | 21 (5) |
| Death | 72 (18) | 64 (16) |
| Progressive disease | 31 (8) | 31 (8) |
| Alternative antileukemia therapy | 3 (<1) | 2 (<1) |
| Patient decision to permanently stop treatment | 23 (6) | 22 (5) |
| Lost to follow-up | 1 (<1) | 0 |
| Other | 10 (2) | 11 (3) |
| Patients, n (%) . | Guadecitabine (n = 408) . | TC (n = 407) . |
|---|---|---|
| <4 cycles | 173 (42) | 166 (41) |
| Primary reason for receiving <4 cycles | ||
| Randomized, but not treated | 7 (2) | 15 (4) |
| AE | 26 (6) | 21 (5) |
| Death | 72 (18) | 64 (16) |
| Progressive disease | 31 (8) | 31 (8) |
| Alternative antileukemia therapy | 3 (<1) | 2 (<1) |
| Patient decision to permanently stop treatment | 23 (6) | 22 (5) |
| Lost to follow-up | 1 (<1) | 0 |
| Other | 10 (2) | 11 (3) |